Merck KGaA Gets FDA Breakthrough-Therapy Designation for Tepotinib

Date : 11/09/2019 @ 20:49
Source : Dow Jones News
Stock : Merck KGaA (PK) (MKKGY)
Quote : 25.79  -1.25 (-4.62%) @ 07:55
Merck KGaA (PK) share price Chart

Merck KGaA Gets FDA Breakthrough-Therapy Designation for Tepotinib

Historical Stock Chart

6 Months : From Aug 2019 to Feb 2020

Click Here for more Merck KGaA (PK) Charts.

By Colin Kellaher


Merck KGaA (MRK.XE) Wednesday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to its tepotinib investigational therapy in a form of lung cancer.

The Darmstadt, Germany, science and technology company said the designation covers tepotinib in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations who progressed following platinum-based cancer therapy.

The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.

Lung cancer is one of the most common types of cancer worldwide. Merck said alterations of the MET signaling pathway are found in 3% to 5% of non-small cell lung cancer cases and correlate with aggressive tumor behavior and poor clinical prognosis.


Write to Colin Kellaher at


(END) Dow Jones Newswires

September 11, 2019 06:34 ET (10:34 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Euro vs Au..
US Dollar ..
BHP Bilito..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:au D:20200225 07:25:11